Menu
Oncology Evolved
with off-the-shelf cellular therapies for cancer
PIPELINE
PRE-CLINICAL
CLINICAL
AML
WU-NK-101
Head & Neck Cancer
WU-NK-101 + Cetuximab
Melanoma
WU-NK-101 (post-checkpoint inhibitor)
Solid Tumors
WU-NK-201
T-ALL
WU-CART-007
LATEST NEWS
Wugen Presents New Preclinical Data Supporting the Safety and Efficacy of WU-CART-007 for T-Cell Malignancies at the 63rd Annual Society of Hematology (ASH) Annual Meeting
WU-CART-007, an allogeneic off-the-shelf CAR-T cell therapy for T-Cell malignancies, has received IND clearance from the FDA WU-CART-007 demonstrates…
Wugen Presents New Preclinical Data from Novel Memory Natural Killer (NK) Platform at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
Wugen’s proprietary platform employs a GMP-grade, feeder cell-free manufacturing process to produce commercially scalable, off-the-shelf, non-engineered memory natural killer (NK)…
Wugen to Present Virtually at the Upcoming Jefferies London Healthcare Conference
ST. LOUIS, MO and SAN DIEGO, CA, November 10, 2021 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline…
Copyright © 2021 Wugen. All Rights Reserved.
a COGNEO design